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OBJECTIVES: SLE is an autoimmune disease with a broad list of differential mani-
festations, further complicating its diagnosis. The objective of this study was to
compare clinical outcomes, resource utilization and costs between patients with
earlier versus later SLE diagnosis.METHODS: Patients aged 18-64 years and at least
2 years of continuous coverage were identified from a large claims database be-
tween January 2000 and June 2010. Confirmed SLE diagnosis required 1 claim for
rheumatologist visits with a diagnostic code for SLE (ICD-9 code:710.0x) and, in
some cases, an additional requirement for  1 claim for a typical SLE medication.
All patients had 12months of continuous baseline eligibility prior to SLE diagno-
sis. SLE probable onset date was identified during the baseline period by the 2nd
claim for antinuclear antibody tests or prodromal symptoms of SLE. Patients were
stratified into Early or Late Diagnosis groups based on time between probable SLE
onset and diagnosis (6 or 6 months, respectively). Patients in each group were
propensity-score matched on age, gender, diagnosis year, region, and health plan
type. Resource use and costs were compared post-diagnosis between groups using
Poisson regression. Per-patient-per-month costs (PMPM) were calculated to ac-
count for differential lengths of SLE periods between groups. RESULTS: There were
4274 matched patients per group. Post-SLE diagnosis, the Early Diagnosis group
had lower rates of non-severe (RR0.95; 95% CI 0.94-0.96) and severe flares
(RR0.83; 95% CI 0.78-0.89)) and hospitalizations (RR0.72 (95% CI 0.68-0.77)) com-
pared to the Late Diagnosis group. Mean inpatient costs were lower for the Early
Diagnosis ($411 PMPM) patients compared to Late Diagnosis patients ($539 PMPM,
P-value0.001). Results were consistent for other cost categories. CONCLUSIONS:
Patients diagnosed with SLE sooner may experience lower flare rates, less health
care utilization and lower costs. This finding needs to be further explored within
the context of background SLE disease activity.
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OBJECTIVES: Subcutaneous adalimumab or etanercept (SQ) used in moderate-to-
severe plaque psoriasis (PsO), may be patient self-administered in settings other
than that of a healthcare provider (HCP) or physician office. This study assessed the
annual number of office visits, over a 4.5-year period, incurred by PsO patients
receiving SQ and compared to PsO patients not receiving biologics (control).
METHODS: Adalimumab/etanercept claims received from the IMS LifeLink™ data-
base (01/01/2005-06/30/2010) were analyzed cross-sectionally and longitudinally.
Patients were aged 18 years at index and had 2 PsO diagnosis codes at anytime.
The cross-sectional analysis included patients with  1 claim for SQ and continu-
ous enrollment for the year of analysis. The longitudinal analysis included patients
with 6/12months pre-/post-index continuous enrollment, 2 SQ claims, 1 derm
visit, no other inflammatory conditions, and the PsO control group. RESULTS: A
total of 11,871 PsO patients receiving SQ (125,857 cumulative outpatient visits) were
included in the cross-sectional analysis (2005-2009). MeanSD HCP and dermatol-
ogy office visits spanned 8.99.1 to 10.29.8 and 2.66.2 to 4.08.0, respectively. A
total of 2,639 patients (27,684 cumulative outpatient visits) were included in the
longitudinal analysis. MeanSD HCP and dermatology office visits were 9.19.6
and 4.48.0, respectively. Mean (median) days between visits was 53.8 (44.3) and
94.0 (86.7) for HCPs and dermatology, respectively. The PsO control group (n38,727
patients) incurred a meanSD of 9.710.5 and 4.08.0 for HCPs and dermatology,
respectively. CONCLUSIONS: Since 2005, PsO patients receiving SQ had a mean of
9 HCP office visits each year. PsO patients, assessed longitudinally for 12 months
after SQ initiation, incurred a similar number of HCP office visits and visited der-
matologists on approximately a quarterly basis. Results were consistent with con-
trol group findings, suggesting that there are similar HCP visit patterns in PsO
patients using SQ and PsO patients not using biologics.
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OBJECTIVES:Currently twomodes of administration are available for biologic ther-
apies used to treat immunology conditions: intravenous infusion (IV) and subcu-
taneous injection (SQ). This study explores patient perceptions of IV biologic ther-
apy for treatment of immunology conditions among patients of different
race/ethnicity. METHODS: Semi-structured telephone interviews were conducted
with 405 immunology patients currently treated with IV biologic therapy. Patients
identified preference for IV or SQ and reasons for preference. Patient perceptions
were assessed by agreement (6agree or 7strongly agree on a 7-point scale) with
a series of statements about mode of administration. RESULTS: The sample in-
cluded 83.5% (n338) Caucasian/White, 7.9% (n32) African-American/Black, and
5.2% (n21) Hispanic. While all patients preferred IV to SQ, African-American/
Black patients had a stronger preference than Caucasian/White patients (96.9% vs.
79.9%, p0.050). Of those preferring IV, a greater proportion of African-American/
Black patients reported not wanting to give self-injections or not liking needles as
a reason for IV preference (71.0% vs. 40.0% for Caucasian/White patients and 38.9%
for Hispanic patients, p0.050 for both). A significantly larger proportion of Afri-
can-American/Black patients agreed with the following statements than Cauca-
sian/White patients (p0.05 for all): IV medications are stronger than non-IVmed-
ications (50.0% vs. 31.7%); an IV infusion would be less painful than injections
(37.5% vs. 23.4%); I don’t like needles and therefore don’t like the idea of having to
give myself injections (46.9% vs. 24.0%); I would be concerned about the risk of
doing harm to myself if I had to give myself injections (40.6% vs. 16.3%); it is easier
for me to schedule an appointment at an infusion center than to remember when
to givemyself injections (37.5% vs. 17.2%).CONCLUSIONS: Patient perceptions of IV
biologic therapy differ by race/ethnicity. Coverage and access policies that limit
availability of IV biologic therapy may disproportionately affect racial/ethnic mi-
norities.
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OBJECTIVES: To assess how health-related quality of life (HRQOL) of patients with
myelodysplastic syndromes (MDS) who were red blood cell transfusion dependent
(RBC TD) at baseline and remained so across six months of treatment with Azaci-
tidine (AZA) compared with HRQOL of MDS patients who were RBC TD at baseline
but became RBC transfusion independent (TI) across sixmonths of AZA treatment.
METHODS: Data were collected in AVIDA®, a prospective registry of patients
treated with AZA. MDS patients who were RBC TD at baseline and who received 56
days or more of AZA were analyzed. RBC TD was verified centrally. Clinicians
provided data on clinical characteristics, including RBC transfusions. Patients com-
pleted the EORTC-QLQ-C30 at baseline and quarterly thereafter. Summary statis-
tics on global health status, functional scales, and symptom/other scales were
analyzed. Statistical significancewas determined byANOVA (SAS 9.1).RESULTS:At
baseline, 85 patients were RBC TD. At 6 months, 41 had achieved RBC TI, while 44
remained RBC TD. Baseline WHO Disease Classification, FAB subtype, IPSS Risk
level and HRQOL of patients who remained RBC TD were comparable and not
statistically different from those who became RBC TI. At six months, global health
status improved among those who became RBC TI, and declined among those who
stayed RBC TD (p0.0140). Statistically significant and clinically meaningful differ-
ences in change between baseline and 6 months were seen in physical and role
function (p0.0005 and p0.0154), but not in emotional, cognitive or social func-
tion. Fatiguewas the only symptom (of 9) in which changeswere different between
groups (p0.0285), with RBC TI patients reporting less fatigue, and RBC TD patients
reporting more. CONCLUSIONS: Findings from AVIDA® indicate that HRQOL
among RBC TD MDS patients treated with AZA improved significantly overall and
on certain domains when RBC TI was achieved.
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OBJECTIVES: Pain treatment is a real challenge for Public Health and a requirement
for the quality and evolution of a health system. It responds primarily to a human-
ist and ethical objective, intrinsic to the dignity of the humankind. The physical
pain and moral suffering experienced during all ages of life make those already
weakened by the disease evenmore vulnerable. Treatment compliance is essential
to the efficacy of the treatment offered. Side effects or undesirable effects may be
caused by non compliance when they appear in the first 24 or 48 hours after treat-
ment. The objectyive is to describe the side effects perceived during the first 48
hours and spontaneously cited by the subjects treated with an analgesic.
METHODS: Prospective, longitudinal, multicenter observational study, conducted
in France using data collected by the general practitioners who agreed to
participate. RESULTS: Patients were treated either with a paracetamol-codeine
combination (n 742) or with a paracetamol-tramadol combination (n107). Nau-
sea / vomiting, dizziness, drowsiness and constipation were the 4 most commonly
cited side effects. In the first group, prevalence after 24h was 9.56%, 2.96%, 4.44%
and 1.08% respectively, versus 13.89%, 7.41%, 2.78%and 2.78% in the second group. On
the 2nd day, prevalence in the first group was 3.9%, 2.01%, 3.4% and 2.8% respectively,
versus11.1%, 3.7%, 1.85%and2.78% in thesecondgroup. Prevalenceofat leastoneside
effect perceived during the 7 days of treatment was 29.74% in the first group versus
40.74% in the second treatment group. CONCLUSIONS: A study published in 2005
(Patients and chronic pain–Exercer magazine January 2005-Le Goaziou et call) indi-
cated 37% constipation, 24% nausea and vomiting and 22.4% dizziness for a group
of patients undergoing treatment. It appeared that the patients treated with one of
the two drug combinations had fewer complaints of the same side effects.
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